Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin Monotherapy or Combo with Irinotecan vs Topotecan in Relapsed SCLC
NCT06496048Phase 3Recruiting
- Sponsor
- Luye Pharma Group
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by Luye Pharma Group. Started Sep 2024; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06496048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496048.